androstane-3,6,17-trione | 500148-41-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: androstane-3,6,17-trione
• 英文别名: (8R,9S,10R,13S,14S)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,6,17-trione
• CAS: 500148-41-4
• 化学式: C₁₉H₂₆O₃
• 分子量: 302.414
• InChiKey: MGUDNDBPVZPSQA-KFJLMCKQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  androstane-3,6,17-trione 、 3-(RS)-pyrrolidinyloxyamine dihydrochloride 在 盐酸 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 0.5h， 以60%的产率得到(E) 3-[3-(RS)-pyrrolidinyl]oxyiminoandrostane-6,17-dione hydrochloride
  参考文献：
  名称：

  WO2007/118830

  摘要：

  公开号：
• 作为产物：
  描述：

  异丙醇 、 androstane-3β,6α,17β-triol 以 水 、 丙酮 为溶剂， 生成 androstane-3,6,17-trione
  参考文献：
  名称：

  Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues

  摘要：

  本文描述了一种改进的方法，用于制备通式为(I)的化合物，特别是用于制备化合物(E,Z)3-(2-氨基乙氧基亚胺基)-雄烷-6,17-二酮，其中n=1且R1=R2=H。

  公开号：

  US20010056182A1

文献信息

• AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
  申请人：Cerri Alberto

  公开号：US20110053902A1

  公开（公告）日：2011-03-03

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na + , K + -ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  化合物的化学式（I），其中：所述基团如描述中所定义，可用于制备用于治疗心血管疾病，特别是心力衰竭和高血压的药物。这些化合物是Na+，K+-ATP酶活性的抑制剂。所述化合物用于制备一种药物，用于治疗由内源性欧巴因的高血压效应引起的疾病，例如在常染色体显性多囊肾病（ADPKD）中肾功能衰竭进展、妊娠期高血压和蛋白尿以及具有adducin多态性的患者中的肾功能衰竭进展。
• AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
  申请人：Cerri Alberto

  公开号：US20090275542A1

  公开（公告）日：2009-11-05

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  式(I)化合物，其中：所述基团如描述中定义的那样，对于制备治疗心血管疾病的药物，特别是心力衰竭和高血压是有用的。这些化合物是Na+，K+-ATPase酶活性的抑制剂。它们对于制备治疗内源性欧巴因引起的疾病的药物是有用的，例如：常染色体显性多囊肾病（ADPKD）中的肾功能衰竭进展、先兆子痫性高血压和蛋白尿，以及具有adducin多态性的患者的肾功能衰竭进展。
• Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
  申请人：Cerri Alberto

  公开号：US08536160B2

  公开（公告）日：2013-09-17

  Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

  式（I）的化合物，其中：所述基团如描述中所定义，用于制备用于治疗心血管疾病，特别是心力衰竭和高血压的药物。这些化合物是Na+，K+-ATPase酶活性的抑制剂。它们用于制备治疗由内源性欧巴因引起的疾病的药物，如常染色体显性多囊肾病（ADPKD）中的肾衰竭进展，先兆子痫性高血压和蛋白尿以及具有加朵因多态性的患者的肾衰竭进展。
• NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS
  申请人：WASHINGTON UNIVERSITY

  公开号：US20150361125A1

  公开（公告）日：2015-12-17

  The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

  本公开涉及具有额外可选取代基团的碳3、4、6、7、10和13的15、16和17位旋光异构的神经活性取代类固醇及其药学上可接受的盐，例如，用作GABA-A受体调节剂。本公开进一步涉及包含这种化合物的制药组合物。
• Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors
  申请人：Washington University

  公开号：US10202413B2

  公开（公告）日：2019-02-12

  The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

  本公开内容一般涉及在碳3、4、6、7、10和13上具有额外任选取代基的神经活性对映体15、16和17-取代类固醇及其药学上可接受的盐，可用作例如GABA-A型受体的调节剂。本公开进一步涉及包含此类化合物的药物组合物。